Economic and clinical aspects of intravenous versus oral busulfan in adult patients for conditioning prior to HSCT

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
Karin BergerHelmut Ostermann

Abstract

Busulfan (BU) used as cytoreductive conditioning prior to hematopoietic stem cell transplantation (HSCT) is available as intravenous (IV) and oral (O) preparation. IV-BU has clinical advantages associated with relevant incremental costs. The aim was to determine the economic impact of IV-BU versus O-BU in adult HSCT recipients from a German health care providers' perspective. A budget-impact model (BIM) including costs and risks for oral mucositis (OM), infection with OM, and hepatic sinusoidal obstruction syndrome (SOS) was developed. Model inputs are literature data comparing clinical effects of IV-BU versus O-BU and German cost data (conditioning therapy, treatment of OM, infections, SOS without/with multiorgan failure) from literature and tariff lists. Base case calculations resulted the following: total costs of adverse events were €86,434 with O-BU and €44,376 with IV-BU for ten patients each. Considering costs of adverse events and drugs, about €5840 for ten patients receiving IV-BU are saved. Sensitivity analyses were conducted in several ways. Cost savings range between €4910 and €12,640 per ten patients for all adverse events and €2070 or €1140 per ten patients considering SOS only. Drug treatment of SOS and treatment...Continue Reading

References

Mar 27, 1999·Annals of Emergency Medicine·W H Cordell
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S J LeeJ H Antin
May 4, 2005·Zeitschrift für Kardiologie·T FürstenbergH Reinecke
Sep 25, 2007·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Josephine A MauskopfPaul Trueman
Jan 16, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·J-Matthias Graf von der SchulenburgUNKNOWN Hanover Consensus Group
Aug 12, 2008·Current Clinical Pharmacology·Christa Ellen Nath, Peter John Shaw
Aug 14, 2008·British Journal of Haematology·A RuggeriG Socié
Apr 14, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Stefan O Ciurea, Borje S Andersson
Sep 22, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jason A CoppellDietger Niederwieser
Feb 20, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Paul G RichardsonEva C Guinan
Feb 24, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B J PaessensA Ihbe-Heffinger
Mar 1, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Hongzheng ZhangEdmund K Waller
Dec 12, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Simrit ParmarSergio Giralt
Dec 13, 2012·Hematology·Steven Z Pavletic, Daniel H Fowler
Apr 16, 2013·Bone Marrow Transplantation·J R PasswegUNKNOWN European Group for Blood and Marrow Transplantation
Oct 10, 2013·British Journal of Haematology·Fiona L DignanUNKNOWN British Society for Blood and Marrow Transplantation

❮ Previous
Next ❯

Citations

Apr 10, 2019·Experimental Biology and Medicine·Ajaikumar B KunnumakkaraBharat B Aggarwal
May 3, 2021·Oral Oncology·Leticia Rodrigues-OliveiraAna Carolina Prado-Ribeiro

❮ Previous
Next ❯

Software Mentioned

IV
Excel
BU
PubMED

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
Montserrat Vera-LlonchStephen Sonis
Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology
Xiao-Bing ChenXiu-Zhen Tong
Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology
Wei ZhaoChengzhi Gao
© 2021 Meta ULC. All rights reserved